Pure Global
NCT06230653

Mechanomyography Reloaded? A Randomized Prospective Agreement Study

A Single-centre, Randomised, Prospective Agreement Study to Determine the Clinical Performance and Safety of a Best Practice Medical Device With a Novel Sensor
University Hospital Ulm·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Neuromuscular Blockade
Study type
Observational
Sponsor & location
Primary sponsor
University Hospital Ulm
Timeline & enrollment
Phase
N/A
Start date
Jan 22, 2024
End date
Apr 30, 2024
Enrollment
40 participants
Primary outcome

Precision of the Mechanomyography

Summary

Neuromuscular monitoring is used to evaluate neuromuscular function intraoperatively and to
 ensure complete neuromuscular recovery at the end of anaesthesia. Therefore, the lack of
 reliable neuromuscular monitoring devices that are not cumbersome to use is a major
 shortcoming for anaesthesia. A recently developed mechanomyography (MMG) device may meet
 these partially unmet needs due to its measurement of the patient's contractile force instead
 of its surrogates (i.e., acceleration, velocity), including the response to physiologically
 relevant tetanic stimulation. However, it is unclear whether the reliability of the newly
 developed MMG device is similar to or better than the currently available gold standard of
 neuromuscular monitoring based on electromyography (EMG).

ICD-10 classifications
Skeletal muscle relaxants [neuromuscular blocking agents]Poisoning: Skeletal muscle relaxants [neuromuscular blocking agents]Other neuromuscular dysfunction of bladderNeuromuscular dysfunction of bladder, unspecifiedNeuromuscular scoliosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06230653
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06230653 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital Ulm and is currently Not yet recruiting. The study focuses on Neuromuscular Blockade. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.